Shave Margins in Breast Conservation Therapy

NCT ID: NCT02462200

Last Updated: 2020-06-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-13

Study Completion Date

2019-11-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators propose a randomized controlled superiority trial of standard breast-conserving surgery (BCS) versus BCS with cavity shave margins (CSM). The main objectives of this trial will be to evaluate prospectively the impact of routine standardized CSM on margin status following primary surgery for early stage breast cancer (Stage 0 - II), on post-operative patient satisfaction and cosmetic outcomes, and on general intraoperative time and operative costs. A parallel group format will be implemented to compare this modified surgical therapy - BCS with CSM - with BCS alone, which is the current standard of care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Cancer of Breast Cancer of the Breast

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BCS Arm (breast-conserving surgery - standard of care)

* Defined as partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization
* The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (except for those patients with iodine or seafood allergies or in cases where the goggles are unavailable for use).
* Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of and CSM that are taken.

Group Type ACTIVE_COMPARATOR

Breast-conserving surgery (BCS)

Intervention Type PROCEDURE

BREAST-Q Questionnaire

Intervention Type BEHAVIORAL

3-D breast imaging

Intervention Type DEVICE

Using a 3-D breast imaging camera Vectra 3-D XT

Indocyanine green

Intervention Type OTHER

Intraoperative imaging device

Intervention Type DEVICE

The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field

Peripheral blood draw

Intervention Type PROCEDURE

-Time of surgery if coordinator is available

CSM Arm (breast-conserving surgery with cavity shave margins)

* Partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization with the addition of additional tissue specimens from all 6 margins (anterior, posterior, superior, inferior, medial, lateral) of the wound cavity if possible. In cases where an additional margin would involve the skin at the anterior margin and/or the pectoral muscle at the posterior margin, only the 4 (or 5) remaining margins should be obtained
* A margin thickness of 1 cm will be the defined goal to establish uniformity among different surgeons and allow for appropriate pathological evaluation
* The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (no iodine or seafood allergies).
* Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of any CSM that are taken.

Group Type EXPERIMENTAL

Breast-conserving surgery (BCS)

Intervention Type PROCEDURE

Cavity shave margins (CSM)

Intervention Type PROCEDURE

BREAST-Q Questionnaire

Intervention Type BEHAVIORAL

3-D breast imaging

Intervention Type DEVICE

Using a 3-D breast imaging camera Vectra 3-D XT

Indocyanine green

Intervention Type OTHER

Intraoperative imaging device

Intervention Type DEVICE

The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field

Peripheral blood draw

Intervention Type PROCEDURE

-Time of surgery if coordinator is available

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Breast-conserving surgery (BCS)

Intervention Type PROCEDURE

Cavity shave margins (CSM)

Intervention Type PROCEDURE

BREAST-Q Questionnaire

Intervention Type BEHAVIORAL

3-D breast imaging

Using a 3-D breast imaging camera Vectra 3-D XT

Intervention Type DEVICE

Indocyanine green

Intervention Type OTHER

Intraoperative imaging device

The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field

Intervention Type DEVICE

Peripheral blood draw

-Time of surgery if coordinator is available

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ICG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed, biopsy-proven stage 0-II breast cancer.
* Planning to undergo breast-conserving surgery.
* At least 18 years of age and no more than 85 years of age.
* Female.
* Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria

* Prior surgical treatment for this diagnosis.
* Undergone neoadjuvant chemotherapy.
* History of prior chest radiation therapy.
* Known metastatic disease.
* Pregnant.
* Preference for mastectomy instead of breast-conserving surgery.
* History of ipsilateral breast cancer.
* Goggle assessment substudy: Iodine or seafood allergies.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Washington University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Julie Margenthaler, M.D.

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.siteman.wustl.edu

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201506053

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Robotic vs. Open NSM for Early Stage Breast Cancer
NCT05720039 ACTIVE_NOT_RECRUITING NA
Tumor: Breast Ratio Study
NCT02216136 COMPLETED
Chronic Post Breast Surgery Pain
NCT00847067 TERMINATED NA